ʻO ke Belt and Road: Ka Launa Pū, ka Lokahi a me ka Lanakila-Lanakila
nā huahana

Nā huahana

Tirzepatide CAS:2023788-19-2 Mea Hana Mea Hoʻolako

Ua hoʻomohala ʻia ʻo Tirzepatide ma ke ʻano he agonist pālua i nā mea loaʻa GLP-1 a me nā mea hoʻokipa polypeptide inhibitory gastric (GIP) (Frias et al., 2018). E like me GLP-1, ʻo GIP kahi hormone incretin e hana ana e hoʻoulu i ka hoʻokuʻu ʻana o ka insulin. Aia ʻo Tirzepatide i ka hoʻomohala ʻana o ka pae 3 no nā pākeke me ka momona a i ʻole ke kaumaha me ka comorbidity e pili ana i ke kaumaha a ke nānā ʻia nei i kēia manawa ma ke ʻano he lāʻau lapaʻau no nā pākeke me ka maʻi diabetes type 2. Ke aʻo ʻia nei hoʻi ia ma ke ʻano he lāʻau lapaʻau kūpono no ka steatohepatitis non-alcoholic (NASH) a me ka hāʻule ʻana o ka puʻuwai me ka mālama ʻia ʻana o ka ejection fraction (HFpEF).


Nā kikoʻī huahana

Nā Lepili Huahana

Hoʻohana a me ka hopena

Hoʻohana ʻia ʻo Tirzepatide me kahi papaʻai kūpono a me ka papahana hoʻoikaika kino e kāohi i ke kō koko kiʻekiʻe i nā poʻe me ka maʻi diabetes type 2. ʻO ka kāohi ʻana i ke kō koko kiʻekiʻe e kōkua i ka pale ʻana i ka hōʻino ʻana o nā puʻupaʻa, ka makapō, nā pilikia aʻalolo, ka nalowale o nā lālā, a me nā pilikia hana moekolohe. ʻOi aku ka pili o Tirzepatide i nā mea loaʻa GIP ma mua o nā mea loaʻa GLP-1, a ua hōʻike ʻia kēia ʻano agonist pālua e hana i ka hōʻemi nui ʻana o ka hyperglycemia i hoʻohālikelike ʻia me kahi agonist receptor GLP-1 koho. Ua hōʻike nā haʻawina hōʻailona ʻo kēia ma muli o ka hoʻohālike ʻana o ka tirzepatide i nā hana o ka GIP kūlohelohe ma ka mea loaʻa GIP.

Laʻana Huahana

图片420(1)
图片320(1)

Hoʻopili Huahana:

图片338(1)

ʻIke Hou Aʻe:

Hoʻonohonoho ʻana ʻAʻole
Hoʻāʻo 99%
helehelena Pauka keʻokeʻo
Helu CAS. 2023788-19-2
Hoʻopili ʻana 25KG
Ola Papa 2 mau makahiki
Ka Waihona E mālama i kahi maloʻo a me kahi anuanu
Palapala hōʻoia ISO.

  • Ma mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou